59 related articles for article (PubMed ID: 10974929)
1. Immunohistochemical study of p53 in non-small cell lung cancer before and after preoperative chemotherapy.
Korobowicz E; Zdunek M
Pol J Pathol; 2000; 51(2):71-6. PubMed ID: 10974929
[TBL] [Abstract][Full Text] [Related]
2. Expression of PCNA in non-small cell lung cancer before and after treatment with cisplatin and vepeside.
Zdunek M; Korobowicz E
Pol J Pathol; 2000; 51(2):77-81. PubMed ID: 10974930
[TBL] [Abstract][Full Text] [Related]
3. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
[TBL] [Abstract][Full Text] [Related]
5. Expression of p53 gene in stage IIIA non-small cell lung cancer in patients after neoadjuvant chemotherapy with Vepesid and Cisplatin.
Mańdziuk S; Dudzisz-Sledź M; Korszeń-Pilecka I; Milanowski J; Wojcierowski J; Korobowicz E
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):154-7. PubMed ID: 15314976
[TBL] [Abstract][Full Text] [Related]
6. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer.
Rusch V; Klimstra D; Venkatraman E; Oliver J; Martini N; Gralla R; Kris M; Dmitrovsky E
Cancer Res; 1995 Nov; 55(21):5038-42. PubMed ID: 7585548
[TBL] [Abstract][Full Text] [Related]
7. P53 immunostaining predicts chemosensitivity in non-small cell lung cancer: A preliminary report.
Kawasaki M; Nakanishi Y; Yatsunami J; Takayama K; Ochiai S; Xinhai P; Kuwano K; Hara N
Cancer J Sci Am; 1996; 2(4):217-20. PubMed ID: 9166535
[TBL] [Abstract][Full Text] [Related]
8. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
[TBL] [Abstract][Full Text] [Related]
9. Expression of p21 and bcl-2 proteins in paraffin-embedded preparations of non-small cell lung cancer in stage IIIA after Etoposide and Cisplatin induced chemotherapy.
Mańdziuk S; Dudzisz-Sledź M; Korszeń-Pilecka I; Milanowski J; Wojcierowski J; Korobowicz E
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):149-53. PubMed ID: 15314975
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer.
Miyatake K; Gemba K; Ueoka H; Nishii K; Kiura K; Tabata M; Shibayama T; Takigawa N; Kawaraya M; Tanimoto M
Anticancer Res; 2003; 23(3C):2829-36. PubMed ID: 12926120
[TBL] [Abstract][Full Text] [Related]
11. 99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis.
Yüksel M; Cermik TF; Doğanay L; Karlikaya C; Cakir E; Salan A; Berkarda S
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):876-81. PubMed ID: 12111127
[TBL] [Abstract][Full Text] [Related]
12. Therapy increases poly-ADP-ribose and p53-Ser392-P levels in recurrent squamous cell lung cancer.
Holownia A; Mroz RM; Kozlowski M; Chyczewska E; Laudanski J; Chyczewski L; Braszko JJ
Neoplasma; 2003; 50(4):266-71. PubMed ID: 12937839
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of p53 status in non-small cell lung cancer in correlation with postoperative adjuvant therapy.
Hanaoka N; Tanaka F; Wada H
Thorac Cardiovasc Surg; 2002 Dec; 50(6):355-9. PubMed ID: 12457313
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis and p53 status predict the efficacy of postoperative administration of UFT in non-small cell lung cancer.
Tanaka F; Otake Y; Yanagihara K; Yamada T; Miyahara R; Kawano Y; Li M; Inui K; Wada H
Br J Cancer; 2001 Jan; 84(2):263-9. PubMed ID: 11161386
[TBL] [Abstract][Full Text] [Related]
15. Glutathione-S transferase-pi expression in non small cell lung cancer in the assessment of response to chemotherapy.
Unsal M; Akpolat I; Kandemir B
Saudi Med J; 2003 May; 24(5):493-8. PubMed ID: 12847624
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of p53 and ras p21 protein expression in surgically treated non-small cell lung carcinoma.
Cohen R; Guber A; Koren R; Marom Z; Siegal A
Rom J Morphol Embryol; 1998; 44(1-4):117-23. PubMed ID: 15678852
[TBL] [Abstract][Full Text] [Related]
17. Y-box-binding protein-1 expression is not correlated with p53 expression but with proliferating cell nuclear antigen expression in non-small cell lung cancer.
Yoshimatsu T; Uramoto H; Oyama T; Yashima Y; Gu C; Morita M; Sugio K; Kohno K; Yasumoto K
Anticancer Res; 2005; 25(5):3437-43. PubMed ID: 16101161
[TBL] [Abstract][Full Text] [Related]
18. Postoperative adjuvant chemotherapy for stage I non-small cell lung cancer.
Park JH; Lee CT; Lee HW; Baek HJ; Zo JI; Shim YM
Eur J Cardiothorac Surg; 2005 Jun; 27(6):1086-91. PubMed ID: 15896623
[TBL] [Abstract][Full Text] [Related]
19. Patient subsets benefiting from adjuvant therapy following surgical resection of non-small cell lung cancer.
Johnson BE; Rabin MS
Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5022s-5026s. PubMed ID: 16000607
[TBL] [Abstract][Full Text] [Related]
20. [P53 protein expression and chemosensitivity to cisplatin in patients with non-small cell lung cancer: a meta-analysis].
Wang JL; Jiao SC; Ye P; Li JY
Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):770-3. PubMed ID: 18504201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
